A randomized phase II trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Stinchcombe, T. E. [1 ]
Janne, P. A. [2 ]
Wang, X. [3 ]
Bertino, E. M. [4 ]
Weiss, J. M. [5 ]
Bazhenova, L. [6 ]
Gu, L. [3 ]
Lau, C. J. [2 ]
Paweletz, C. P. [2 ]
Jaslowski, A. J. [7 ]
Gerstner, G. J. [8 ]
Baggstrom, M. Q. [9 ]
Graziano, S. L. [10 ]
Beardenlii, J. [11 ]
Vokes, E. E. [12 ]
机构：
[1] Duke Canc Ctr, Med Oncol, Durham, NC USA
[2] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA
[3] Duke Univ, Dept Biostat & Bioinformat, Durham, NC USA
[4] Ohio State Univ, James Canc Hosp, Med Oncol, Columbus, OH 43210 USA
[5] Univ North Carolina Chapel Hill, Hematol Oncol, Chapel Hill, NC USA
[6] Moores UCSD Canc Ctr, Med, La Jolla, CA USA
[7] St Marys Hosp, Med Oncol, Green Bay, WI USA
[8] Illinois CancerCare PC, Med Oncol, Peoria, IL USA
[9] Washington Univ, Sch Med, Med Oncol, St Louis, MO USA
[10] SUNY Upstate Med Univ, Med Oncol, Syracuse, NY 13210 USA
[11] Palmetto Hematol Oncol Associates, Med Oncol, Spartanburg, SC USA
[12] Univ Chicago, Med Ctr, Med Oncol, Chicago, IL 60637 USA
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1444P
引用
收藏
页码：522 / 522
页数：1
相关论文
共 50 条
  • [1] A randomized phase II study comparing erlotinib with or without bevacizumab in patients with advanced non-small cell lung cancer (NSCLC) with EGFR mutation.
    Lee, Youngjoo
    Kim, Hye Ryun
    Hong, Min Hee
    Lee, Ki Hyeong
    Park, Keon Uk
    Lee, Geon Kook
    Kim, Hyae Young
    Lee, Soo-Hyun
    Lim, Kun Young
    Yoon, Sung Jin
    Cho, Byoung Chul
    Han, Ji-Youn
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] Phase I trial of vorinostat in combination with erlotinib in advanced non-small cell lung cancer (NSCLC) patients with EGFR mutations after erlotinib progression
    Reguart, N.
    Cardona, A. F.
    Isla, D.
    Cardenal, F.
    Palmero, R.
    Carrasco-Chaumel, E.
    Rolfo, C.
    Massuti, B.
    Moran, T.
    Rosell, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [3] Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer
    Halmos, Balazs
    Pennell, Nathan A.
    Fu, Pingfu
    Saad, Shumaila
    Gadgeel, Shirish
    Otterson, Gregory A.
    Mekhail, Tarek
    Snell, Michael
    Kuebler, Philip
    Sharma, Neelesh
    Dowlati, Afshin
    ONCOLOGIST, 2015, 20 (11): : 1298 - 1303
  • [4] Phase I trial of vorinostat in combination with erlotinib for advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations after erlotinib progression
    Reguart, Noemi
    Isla, Dolores
    Cardenal, Felipe
    Cardona, Andres
    Palmero, Ramon
    Moran, Teresa
    Rolfo, Christian Diego
    Nadal, Ernesto Samuel
    Massuti, Tomeu
    Montanes, Ana
    Queralt, Cristina
    Taron, Miquel
    Rosell, Rafael
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S708 - S708
  • [5] Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial
    Stinchcombe, Thomas E.
    Janne, Pasi A.
    Wang, Xiaofei
    Bertino, Erin M.
    Weiss, Jared
    Bazhenova, Lyudmila
    Gu, Lin
    Lau, Christie
    Paweletz, Cloud
    Jaslowski, Anthony
    Gerstner, Gregory J.
    Baggstrom, Maria Q.
    Graziano, Stephen
    Bearden, James, III
    Vokes, Everett E.
    JAMA ONCOLOGY, 2019, 5 (10) : 1448 - 1455
  • [6] Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
    Li, Ruijian
    Li, Weiyi
    Zhang, Fang
    Li, Shanshan
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2023, 28 (01)
  • [7] Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
    Ruijian Li
    Weiyi Li
    Fang Zhang
    Shanshan Li
    European Journal of Medical Research, 28
  • [8] Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer
    Garon, Edward B.
    Siegfried, Jill M.
    Stabile, Laura P.
    Young, Patricia A.
    Marquez-Garban, Diana C.
    Park, David J.
    Patel, Ravi
    Hu, Eddie H.
    Sadeghi, Saeed
    Parikh, Rupesh J.
    Reckamp, Karen L.
    Adams, Brad
    Elashoff, Robert M.
    Elashoff, David
    Grogan, Tristan
    Wang, He-Jing
    Dacic, Sanja
    Brennan, Meghan
    Valdes, Yacgley
    Davenport, Simon
    Dubinett, Steven M.
    Press, Michael F.
    Slamon, Dennis J.
    Pietras, Richard J.
    LUNG CANCER, 2018, 123 : 91 - 98
  • [9] Phase II trial of concurrent erlotinib in locally advanced non-small cell lung cancer (LA-NSCLC)
    Hansen, O.
    Knap, M.
    Khalil, A.
    Nyhus, C.
    Brink, C.
    Hoffmann, L.
    Schytte, T.
    RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S663 - S663
  • [10] ERLOTINIB IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) TREATMENT
    Goncalves, Ivone M.
    Monteiro, Regina
    Neves, Sofia
    Conde, Sara
    Campainha, Sergio
    Parente, Barbara
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1298 - S1298
12345